Uterine cervical carcinoma is the commonest form of gynecological malignancy in Bangladesh as well as in South Asia. Outcome of weekly versus three weekly Cisplatin concurrent with External beam radiotherapy followed by intracavitary radiotherapy in locally advanced cervical carcinoma was compared in this study.
INTRODUCTION
Almost nine out of ten (87%) uterine cervical cancer deaths occur in the less developed regions. 1 Carcinoma uterine cervix is the second leading cancer among women in Bangladesh. 2 One third cervical cancer cases of the world are found in the South Asian region, especially in India, Bangladesh, Nepal and Pakistan. 3 Concurrent chemoradiotherapy (CCRT) is the cornerstone of management for FIGO Stage IIB-IVA disease. 4 Meta-analysis of some studies (from 1981 to 2000) on chemoradiation for cervical cancer demonstrates improved local control and overall survival with concurrent Cisplatin based chemoradiotherapy. 5 Most commonly practiced concurrent schedule is weekly Cisplatin during radiotherapy. But study shows that three weekly Cisplatin is more effective and less Free Full Text Articles are Available at www.jnma.com.np toxic than weekly Cisplatin. 6 The objective of this study is to observe and compare the outcome of treatment given by weekly versus three weekly concurrent Cisplatin chemoradiotherapy in locally advanced uterine cervical carcinoma.
METHODS
This was a Quasi-Experimental study to compare the treatment outcome between radiotherapy concurrent with weekly versus three weekly Cisplatin in the management of locally advanced carcinoma of uterine cervix. The study was conducted at Department of Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU) and Department of Radiation Oncology, National Institute of Cancer Research and Hospital (NICRH), Dhaka from April 2016 to September 2017. Ethical approval was taken from the Institutional Review Board (IRB) of BSMMU (No. BSMMU/2016/3657 dated 30-03-2016). Sample size was calculated by following formula:
(p1-p2) p1 = 66.5%, p2 = 88.7%, Zα = 1.96, Zβ = 1.28
According to above formula the sample size was needed to be 68 in each Arm, but a total of 80 patients were collected during the study period due to time constrain. Initially patients were selected purposively who met the set inclusion criteria. Then patients were enrolled in either Arm A or Arm B in alternate manner. Inclusion criteria for this study was, clinically diagnosed and histopathologically proven squamous cell carcinoma of uterine cervix FIGO stage IIB to IVA with ECOG performance status 0-2 and no history of prior chemotherapy, radiotherapy or total hysterectomy. Informed written consent was taken from all participated patients.
Forty patients were included in Arm A and received External beam radiotherapy(EBRT), 50Gray (Gy) in 25 fractions over 5 weeks, concurrent with weekly Cisplatin. Arm B included another 40 patients and had received EBRT, 50Gy in 25 fractions over 5 weeks, concurrent with three weekly Cisplatin. Brachytherapy was started one week after the completion of EBRT. Urinary bladder and rectal doses were monitored.
Cisplatin, 40 mg/m 2 was given weekly to the patients of Arm A on day 1 with 250 ml 0.9% intravenous normal saline over 1 to 2 hour before radiotherapy. The schedule was repeated weekly for 6 weeks. The patients of Arm B received Cisplatin, 75 mg/m 2 with 250 ml 0.9% intravenous normal saline on day 1, over 1 to 2 hours before radiotherapy. The schedule was repeated three weekly for three cycles.
Premedication (with Ondansetron, Dexamethason and Ranitidine) was given and at least 1 to 3 liters of 0.9% sodium chloride solution depending on the dose of Cisplatin was given to all the patients for hydration. The patients were also asked to take plenty of fluid before and after Cisplatin infusion.
One week after the completion of concurrent chemoradiotherapy, High dose-rate intracavitary radiotherapy (HDR ICRT) was started. All the patients of both the Arms were treated with HDR ICRT, 7Gy per fraction, 3 fractions in consecutive three weeks with a total dose of 21 Gy to the point A. The total duration of the treatment was within 8 weeks. 
RESULTS
From April 2016 to September 2017, a total of 127 patients were assessed for eligibility and a total of 80 patients were included in this study following the inclusion criteria ( Fig.1 (Table 3 ). The most prevalent acute toxicities in both the Arms were hematological, nephrological, neurological and gastrointestinal origins. Skin toxicities, vaginal mucositis and rectal toxicities were also observed.
In this study, grade III and IV neutropenia observed during concurrent chemoradiotherapy was higher in weekly than in three weekly Cisplatin Arm. In Arm A, 17 (42.5%) patient experienced Grade III-IV neutropenia, whereas in Arm B, it was observed in 8 (20%) patients. This observation is statistically significant (P=0.03), as because of shorter recovery time in weekly Cisplatin than that of three weekly schedule. This variation (neutropenia) was also seen in other studies. 10, 11 However adverse effects were well tolerated and manageable. 11, 12 From these findings it can be said that Free Full Text Articles are Available at www.jnma.com.np three weekly Cisplatin is more compliant and convenient than weekly Cisplatin.
CONCLUSIONS
Concurrent chemoradiation with three weekly Cisplatin is effective, tolerable, and less toxic than weekly Cisplatin in the treatment of locally advanced carcinoma cervix.
